What does the EndoPredict® report tell clinicians?

EndoPredict Breast Cancer Prognostic Test is a gene expression test that provides clear, actionable results for every eligible woman with ER positive/HER2 negative early-stage breast cancer.

Information for clinicians & pathologists

EndoPredict answers 3 key clinical questions

EndoPredict provides fast, easy to interpret results at the right time for clinicians and their breast cancer patients to make confident decisions. Each patient’s breast cancer recurrence risk is calculated using the EPclin Risk Score, which combines clinical and molecular factors for enhanced prognostic performance, supporting accurate decisions.1

EndoPredict is the only second generation test with a clear classification into low-risk and high-risk groups, and has a reliable cut-off value that has never changed.

Will adjuvant chemotherapy be needed?

What is her risk of recurrence at 10 years?

Will chemotherapy be of benefit?

Do the benefits of chemotherapy outweigh the risk of side-effects?

Can extended endocrine therapy be avoided?

What is her risk of recurrence at 15 years?

EndoPredict report pages

The EndoPredict test report makes it easy to interpret each patient’s risk of recurrence, providing actionable results and allowing you to make fast, safe decisions for your patient.

Click below to see an example report and what each page tells you.

EndoPredict_Interactive 1
EndoPredict_Interactive 2
EndoPredict_Interactive 3
EndoPredict_Interactive 4

EndoPredict_Interactive 1

EndoPredict_Interactive 2

EndoPredict_Interactive 3

EndoPredict_Interactive 4

Learn more about how EndoPredict works

If you are a patient, please speak to your doctor about how EndoPredict can help you or visit our patient homepage for more information.

If you are a pathologist looking for the EndoPredict report generator, please visit our pathologist page.

EndoPredict second generation test can be performed locally within a few days

EndoPredict Breast Cancer Prognostic Test is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.

Order a test

News

Sign up for our newsletter

References

  1. Filipits, Martin et al. “A New Molecular Predictor Of Distant Recurrence In ER-Positive, HER2-Negative Breast Cancer Adds Independent Information To Conventional Clinical Risk Factors“. Clinical Cancer Research, vol 17, no. 18, 2011, pp. 6012-6020
  2. Sestak, Ivana et al. “Prediction Of Chemotherapy Benefit By Endopredict In Patients With Breast Cancer Who Received Adjuvant Endocrine Therapy Plus Chemotherapy Or Endocrine Therapy Alone“. Breast Cancer Research And Treatment, vol 176, no. 2, 2019, pp. 377-386
  3. Filipits, Martin et al. “Prediction Of Distant Recurrence Using Endopredict Among Women With ER+, HER2− Node-Positive And Node-Negative Breast Cancer Treated With Endocrine Therapy Only“. Clinical Cancer Research, vol 25, no. 13, 2019, pp. 3865-3872
  4. Dubsky, Peter et al. “The Endopredict Score Provides Prognostic Information On Late Distant Metastases In ER+/HER2− Breast Cancer Patients“. British Journal Of Cancer, vol 109, no. 12, 2013, pp. 2959-2964
  5. Sestak, Ivana et al. “Comparison Of The Performance Of 6 Prognostic Signatures For Estrogen Receptor–Positive Breast Cancer“. JAMA Oncology, vol 4, no. 4, 2018, pp. 545-553

Locations

United States
Europe
Japan